Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT00095641
Other study ID # CDR0000394169
Secondary ID S0225U10CA032102
Status Withdrawn
Phase Phase 2
First received November 5, 2004
Last updated November 7, 2013

Study information

Verified date November 2013
Source Southwest Oncology Group
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving capecitabine after surgery may kill any remaining tumor cells.

PURPOSE: This phase II trial is studying how well capecitabine works in treating patients who have undergone surgery for locally recurrent or persistenthead and neck cancer.


Description:

OBJECTIVES:

- Determine 2-year disease-free survival of patients treated with surgical salvage followed by adjuvant low-dose capecitabine for locally recurrent or persistent squamous cell carcinoma of the head and neck .

- Determine the toxic effects of this drug in these patients.

- Determine 2-year overall survival of patients treated with this drug.

- Determine patterns of disease relapse in patients treated with this drug.

OUTLINE: This is a multicenter study.

Patients receive oral capecitabine once daily for 12 months in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically.

PROJECTED ACCRUAL: A total of 70 patients will be accrued for this study within 2 years.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed squamous cell carcinoma of the head and neck

- Locoregionally recurrent or persistent disease

- No thyroid gland, salivary gland, or nasopharynx disease sites

- Must have undergone definitive or post-operative radiotherapy at the time of initial curative treatment

- Must have undergone salvage surgical resection within the past 56 days

- All current disease must be completely resected, including resection of recurrent primary disease and/or neck dissection, if regional nodal disease is present

- Surgical margins must be free of disease on final pathological evaluation of specimens

- No definitive or adjuvant radiotherapy or reirradiation for recurrent or persistent disease allowed at the time of salvage treatment

- No evidence of distant disease by clinical examination and CT scan of the chest and upper abdomen (including the liver) within the past 90 days

PATIENT CHARACTERISTICS:

Age

- 18 and over

Performance status

- Zubrod 0-1

Life expectancy

- Not specified

Hematopoietic

- Absolute neutrophil count = 1,500/mm^3

- Platelet count = 100,000/mm^3

Hepatic

- Not specified

Renal

- Creatinine clearance = 30 mL/min

Other

- Not pregnant or nursing

- Fertile patients must use effective contraception

- Able to take oral tablets OR able to take crushed tablets through a gastrostomy tube

- No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix

PRIOR CONCURRENT THERAPY:

Biologic therapy

- No concurrent biologic therapy

- No concurrent filgrastim (G-CSF)

Chemotherapy

- Prior systemic chemotherapy as definitive therapy for head and neck cancer allowed (prior treatment with fluorouracil allowed, but must be catalogued)

- More than 5 years since prior systemic chemotherapy for any other cancer diagnosis

- No other concurrent chemotherapy

Endocrine therapy

- No concurrent anticancer hormonal therapy

- Concurrent hormonal therapy for non-cancer diagnosis allowed

Radiotherapy

- See Disease Characteristics

- No concurrent radiotherapy

Surgery

- See Disease Characteristics

- Recovered from prior surgery

Study Design

Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
capecitabine

Procedure:
adjuvant therapy

chemotherapy


Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Southwest Oncology Group National Cancer Institute (NCI)
See also
  Status Clinical Trial Phase
Completed NCT01155609 - L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer N/A
Completed NCT01044433 - Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck Phase 2
Completed NCT00407810 - Cetuximab and Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Phase 2
Completed NCT00098631 - Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer Phase 2
Completed NCT00096512 - S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Phase 2
Completed NCT00055770 - Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer Phase 1/Phase 2
Completed NCT00470496 - Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer Phase 1
Terminated NCT01249443 - Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection Phase 1
Completed NCT01637194 - Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer Phase 1
Completed NCT00033618 - Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Phase 2
Withdrawn NCT01674374 - Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy Phase 2
Completed NCT01816984 - PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Phase 1/Phase 2
Terminated NCT01528137 - Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer Phase 1
Active, not recruiting NCT01847326 - Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer Phase 1
Completed NCT00114283 - Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Phase 2
Completed NCT00055913 - Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Phase 1/Phase 2
Completed NCT01334177 - TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck Phase 1
Completed NCT00492089 - Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Phase 2
Completed NCT00939627 - Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab Phase 2
Terminated NCT00906360 - Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck Phase 1